Brent Meadows
Chief Business Officer Polymed Biopharmaceuticals
Brent is a fractional Chief Business Officer leading the strategy and US business development and partnering efforts for multiple innovative biotech companies, including Hangzhou’s Polymed BioPharmaceuticals. Brent served as the CBO at OncoOne, where he defined the company’s overall business strategy and oversaw all aspects of business development including deal execution. Over his career, Brent has held senior level positions in business development, commercial strategy and marketing positions at Regeneron Pharmaceuticals, Bristol Myers Squibb Oncology, Biogen and several senior positions at Johnson and Johnson. While at AVEO Oncology and Baxalta/Shire he led or co-led multiple transactions each worth over $1 billion. He has an MBA from Babson College and a Bachelor’s of Science in Finance from the University of Richmond.
Seminars
Effective degrader development relies on precise optimization of key molecular properties to ensure robust, reliable degradation efficiency. Explore how to measure these essential properties, build a process for efficient optimization, and develop a platform to create degraders quickly and reliably. Featuring real-world case studies, this session offers practical strategies to streamline degrader design for maximum therapeutic impact. We will cover:
- The creation of HPB-143/VP-776: an optimized IRAK4 PROTAC modeled against the benchmark KT-474
- Identification and development of BCL-XL protein degraders
- Is ternary complex kinetic stability a key driver of degradation efficiency?
